TAILORx

Susan G. Komen has been concerned for years about the toxic side effects of chemotherapy. The TAILORx study, which was supported in part by Komen funding, suggests that through genomic testing we can find out more precisely if a breast cancer patient would benefit from chemotherapy or not.